Aug 8, 2016

SCYNEXIS, Inc. Reports Second Quarter 2016 Financial Results and Provides Company Update

 Positive Results from Two Phase 2 Studies Confirm Antifungal Clinical Activity of SCY-078 

Company is Well Positioned and Capitalized to Advance its Clinical Programs Forward As Planned 

JERSEY CITY, N.J., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX), a pharmaceutical company developing novel anti-infectives, today reported financial results for the quarter ended June 30, 2016, and provided an update on recent operational and clinical developments. 

"We made significant progress during the second quarter of 2016, achieving our stated clinical and financial goals and further advancing our lead product candidate SCY-078, a novel triterpenoid and structurally distinct glucan synthase inhibitor," said Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS. "We reported positive top-line results from our proof-of-concept Phase 2 study of SCY-078 in patients with acute vulvovaginal candidiasis, and these results were further validated in August 2016 by the positive findings from our Phase 2 study in patients with invasive candidiasis.  Both announcements represent major milestones for the Company, confirming the clinical antifungal activity of oral SCY-078 in patients with Candida infections. Our development path forward is clear, and we believe SCY-078, as a new class, has the potential to be a transformative antifungal therapy, addressing urgent medical needs, particularly as resistance to current therapies is rapidly growing." 

Corporate Update 

SCY-078 Update 

Second Quarter 2016 Financial Results 

Cash, cash equivalents and short-term investments totaled $50.3 million as of June 30, 2016, with net working capital of $48.2 million. 

Research and development, net expenses increased to $6.7 million in the second quarter of 2016, compared to $3.3 million in the second quarter of 2015. The increase of $3.4 million was primarily due to an increase of $1.5 million in clinical development, an increase of $1.1 million in chemistry, manufacturing, and controls (CMC), an increase of $0.4 million preclinical development, and an increase of $0.4 million in other research and development costs. 

Loss from continuing operations for the second quarter of 2016 was $8.1 million, compared to a loss from continuing operations of $6.5 million for the second quarter of 2015. The $1.6 million increase in the loss from continuing operations between the two periods was due to the $3.4 million increase in research and development net expenses offset by a decrease of $1.6 million in selling, general, and administrative expenses. 

Loss from discontinued operations for the second quarter of 2016 was $0.0 million, compared to loss from discontinued operations of $3.0 million for the second quarter of 2015. 

Net loss attributable to common stockholders for the second quarter of 2016 was $8.1 million, or $0.56 per share. This compares to net loss attributable to common stockholders for the second quarter of 2015 of $9.5 million, or $0.78 per share. 

About SCYNEXIS, Inc. 

SCYNEXIS is a pharmaceutical company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and IV drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections in humans. For more information, visit

Forward Looking Statement 

Statements contained in this press release regarding matters that are expected to occur in the future are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, any statements related to SCYNEXIS' continued growth, that it has sufficient capital, that it will release complete data from its Phase 2 study of SCY-078 in patients with VVC, that it will initiate on the  scheduled expected additional studies of SCY-078, and that it will complete the Phase 1 clinical trial  of the IV formulation of SCY-078 and report results in the third quarter of 2016, with top-line data anticipated in November 2016. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited, risks inherent in SCYNEXIS' ability to successfully develop SCY-078, including SCYNEXIS' ability to obtain FDA approval for SCY-078, the expected costs of studies and when they might begin or be concluded, and SCYNEXIS' reliance on third parties to conduct SCYNEXIS' clinical studies. Risks are described more fully in SCYNEXIS' filings with the Securities and Exchange Commission, including without limitation its   most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

(in thousands, except share and per share data)
 Three Months Ended June 30,
  2016  2015
Revenue$64  $64 
Operating expenses:   
Research and development, net6,659  3,282 
Selling, general and administrative1,673  3,275 
Total operating expenses8,332  6,557 
Loss from operations(8,268) (6,493)
Other (income) expense:   
Warrant liability fair value adjustment (101)   
Interest income(39) (1)
Total other income(140) (1)
Loss from continuing operations(8,128) (6,492)
Discontinued operations:   
Loss from discontinued operations  (3,005)
Net loss$(8,128) $(9,497)
Loss per share attributable to common stockholders - basic and diluted   
Continuing operations$(0.56) $(0.53)
Discontinued operations  (0.25)
Net loss per share - basic and diluted$(0.56) $(0.78)
Weighted average common shares outstanding:   
Basic and diluted14,590,733  12,249,487 

(in thousands)
  June 30, 2016  December 31, 2015 
Cash and cash equivalents$37,865  $46,985  
Short-term investments 12,472     
Total current assets 52,738   48,437  
Total assets 53,524   49,273  
Total current liabilities 4,523   6,664  
Total liabilities 9,649   7,324  
Total stockholders' equity 43,875   41,949  
Total liabilities and stockholders' equity 53,524   49,273  

Media Relations
Heather Savelle
MacDougall Biomedical Communications
Tel: 781-235-3060

Investor Relations
Susan Kim
Argot Partners
Tel: 212.203.4433